Altogether, our results demonstrate that NCI-41356 is able to inhibit the progression of pulmonary fibrosis when it is injected locally (intratracheal) or systemically (intravenous) by interfering with TGF-β1 signaling (Figure 5). The gene discussed is TGFB1; the disease is pulmonary fibrosis.